SOX9 expression predicts relapse of stage II colon cancer patients
نویسندگان
چکیده
منابع مشابه
Assessment of prognosis in patients with stage II colon cancer
Pathologic staging is currently the most important prognostic factor in colon cancer, although individually this procedure does not provide a complete clinical outcome. This study aimed to determine the disease-specific survival of patients with colon cancer treated in the Braga Hospital from January 2005 to December 2013, according to the American Joint Committee on Cancer, 6th edition, and th...
متن کاملPreoperative thrombocytosis predicts prognosis in stage II colorectal cancer patients
PURPOSE Thrombocytosis is known to be a poor prognostic factor in several types of solid tumors. The prognostic role of preoperative thrombocytosis in colorectal cancer remains limited. The aim of this study is to investigate the prognostic role of preoperative thrombocytosis in stage II colorectal cancer. METHODS Two hundred eighty-four patients with stage II colorectal cancer who underwent ...
متن کاملAberrant expression of miRNAs predicts recurrence and survival in stage-II colorectal cancer patients from Egypt
Background: Patients with stage II CRC have a varying survival outcome. Therefore, it is critical to identify prognostic biomarkers that can define more aggressive forms of the disease. We assessed the expression levels of five miRNAs that have been previously addressed in relation to the development and progression of solid and hematological tumors. Methods: We measured the expression levels o...
متن کاملBARD1 expression predicts outcome in colon cancer.
PURPOSE BARD1 is a BRCA1-binding partner with tumor suppressive properties. Aberrant splice variants of BARD1 have been detected in various cancers, and it has been postulated that the presence of some splice variants is cancer specific. This is the first study assessing BARD1 expression patterns and correlation with clinical outcome in colon cancer. EXPERIMENTAL DESIGN We analyzed colon canc...
متن کاملAdjuvant chemotherapy for stage II colon cancer.
The use of adjuvant chemotherapy following resection for all patients with stage III colon cancer is now part of the standard of care around the world. Recent trials have led to changes in the standard regimens, which now include the use of oxaliplatin (Eloxatin) for most patients with stage III colon cancer. The addition of oxaliplatin has resulted in a 23% reduction in the risk of recurrence ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Human Pathology
سال: 2016
ISSN: 0046-8177
DOI: 10.1016/j.humpath.2015.12.026